Evidence map›Paper›PMID 12379573›Full record

Trial reportCirculation2002

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.

Allen J Taylor, Steven M Kent, Patrick J Flaherty, Louis C Coyle, Thor T Markwood, Marina N Vernalis

2 registry-linked trialsOpen access · bronzeAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 105 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 9 pooled it
45.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00397657 phase4terminatedstarted 2006, after this paper: background citation

ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)

Ran2006Enrolled400Registered outcomes5Posted comparisons0ConditionsAtherosclerosisArmsExtended release niacin, Ezetimibe
PMID 11757504PMID 12505224PMID 8248954PMID 7886711PMID 7743614PMID 2243429PMID 2215615PMID 17076985PMID 15537681PMID 14996776PMID 8616937other papers from this trial
Open the trial in the graph
NCT01291641 phase4completednot on this mapstarted 2011, after this paper: background citation

Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study

TypeinterventionalSponsorSeoul National University HospitalRan2011 to 2017Enrolled342ConditionsHyperlipidemiasArmsHMG-CoA Reductase Inhibitor, Probucol, Cilostazol
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 9 syntheses or guidelines pooled it, 568 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Prevention of atherosclerosis in patients living with HIV.Vascular health and risk management · 2009
    Trial
  20. Trial

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Allen J TaylorCardiology Service, Walter Reed Army Medical Center, Washington, DC 20307-5001, and USA. allen.taylor@na.amedd.army.mil
Steven M Kent
Patrick J Flaherty
Louis C Coyle
Thor T Markwood
Marina N Vernalis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether marked LDL reduction to levels well below 100 mg/dL would further reduce the burden of cardiovascular disease is controversial. We compared the effects of 2 statins with widely differing potencies for LDL reduction (pravastatin 40 mg/d and atorvastatin 80 mg/d) on carotid intima-media thickness (CIMT). METHODS AND

resultsThis was a single-center, randomized, clinical trial of 161 patients (mean age, 60 years; 71.4% male; 46% with known cardiovascular disease) that met National Cholesterol Education Program (NCEP) II criteria for lipid-lowering therapy. The effects of atorvastatin (80 mg/d; n=79) and pravastatin (40 mg/d; n=82) on CIMT were compared using blinded, serial assessments of the far wall of the distal common carotid artery. Baseline CIMT and other characteristics were similar between study groups. As anticipated, atorvastatin was substantially more potent for LDL reduction after 12 months: in the atorvastatin group, LDL cholesterol was 76+/-23 mg/dL after 12 months (-48.5%); LDL cholesterol was 110+/-30 mg/dL in the pravastatin group (-27.2%; P<0.001). Atorvastatin induced progressive CIMT regression over 12 months (change in CIMT, -0.034+/-0.021 mm), whereas CIMT was stable in the pravastatin group (change of 0.025+/- 0.017 mm; P=0.03).

conclusionsMarked LDL reduction (<100 mg/dL) with a high-potency statin provides superior efficacy for atherosclerosis regression at 1 year. This early effect on CIMT, a surrogate for clinical benefit, suggests that marked LDL reduction with synthetic statins may provide enhanced reduction in clinical coronary event rates.

Indexed as

AdultArteriosclerosisAtorvastatinCarotid ArteriesCholesterolCholesterol, LDLEndpoint DeterminationFemaleHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasLipidsMaleMiddle AgedPravastatinAtorvastatinCholesterolCholesterol, LDLHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsPravastatinPyrroles

Identifiers

PMID12379573
OpenAlexW2122146058

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.